Aberdeen Group plc Increases Stake in Sarepta Therapeutics, Inc. $SRPT

Aberdeen Group plc increased its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 13.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,251,593 shares of the biotechnology company’s stock after purchasing an additional 268,829 shares during the period. Aberdeen Group plc owned approximately 2.15% of Sarepta Therapeutics worth $48,454,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of SRPT. CWM LLC raised its holdings in shares of Sarepta Therapeutics by 4,033.3% in the 3rd quarter. CWM LLC now owns 72,705 shares of the biotechnology company’s stock valued at $1,401,000 after purchasing an additional 70,946 shares in the last quarter. 683 Capital Management LLC boosted its stake in shares of Sarepta Therapeutics by 309.1% during the second quarter. 683 Capital Management LLC now owns 675,000 shares of the biotechnology company’s stock valued at $11,542,000 after purchasing an additional 510,000 shares in the last quarter. Edgestream Partners L.P. increased its holdings in Sarepta Therapeutics by 870.3% during the second quarter. Edgestream Partners L.P. now owns 82,979 shares of the biotechnology company’s stock valued at $1,419,000 after buying an additional 74,427 shares during the period. Boxer Capital Management LLC raised its stake in Sarepta Therapeutics by 900.0% in the third quarter. Boxer Capital Management LLC now owns 250,000 shares of the biotechnology company’s stock worth $4,818,000 after buying an additional 225,000 shares in the last quarter. Finally, Mirador Capital Partners LP bought a new position in Sarepta Therapeutics in the fourth quarter worth approximately $3,012,000. Institutional investors own 86.68% of the company’s stock.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Stephen Mayo sold 7,239 shares of the stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $17.02, for a total value of $123,207.78. Following the sale, the director owned 1,765 shares of the company’s stock, valued at $30,040.30. This trade represents a 80.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

SRPT has been the topic of several recent research reports. Wells Fargo & Company dropped their target price on Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Jefferies Financial Group restated a “buy” rating and set a $30.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 3rd. Royal Bank Of Canada lifted their target price on Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research note on Thursday, January 8th. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a research report on Thursday, March 26th. Finally, Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a report on Tuesday, March 3rd. Nine investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and six have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $32.59.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $23.23 on Friday. The company has a 50 day moving average price of $18.77 and a 200 day moving average price of $20.15. Sarepta Therapeutics, Inc. has a fifty-two week low of $10.41 and a fifty-two week high of $64.80. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. The stock has a market capitalization of $2.44 billion, a P/E ratio of -2.75, a PEG ratio of 0.36 and a beta of 0.29.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($2.71). The firm had revenue of $442.93 million during the quarter, compared to analyst estimates of $390.95 million. Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The business’s revenue was down 32.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.90 earnings per share. Equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.